Addressing D.R.E.S.S. Podcast

Episode 5: Risk Factors and the First Signs: An Interview with Dr. Elizabeth Phillips

November 30, 2020 Dr. Elizabeth J. Phillips Season 1 Episode 6
Episode 5: Risk Factors and the First Signs: An Interview with Dr. Elizabeth Phillips
Addressing D.R.E.S.S. Podcast
More Info
Addressing D.R.E.S.S. Podcast
Episode 5: Risk Factors and the First Signs: An Interview with Dr. Elizabeth Phillips
Nov 30, 2020 Season 1 Episode 6
Dr. Elizabeth J. Phillips

In this episode, we talk with world-renowned DRESS Syndrome expert, Dr. Elizabeth Phillips. She and her colleagues at Vanderbilt University Medical Center are working to better understand the genetic factors that increase a patient's risk for developing  life-threatening, immune-mediated drug reactions - with a focus on simple, inexpensive diagnostic tests can save countless lives.

Interview: Dr. Elizabeth J. Phillips (Professor of Medicine, Pharmacology, Pathology, Microbiology and Immunology and is Director of Personalized Immunology at the Oates Institute for Experimental Therapeutics at Vanderbilt University Medical Center. Lead Scientific Advisor for DRESS Syndrome Foundation) August, 2019 in Bethesda, MD

PUBLICATIONS/RESOURCES:

Vanderbilt Institute for Infection, Immunology and Inflammation: https://www.vumc.org/viiii/person/elizabeth-j-phillips-md
HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms: https://www.sciencedirect.com/science/article/pii/S0091674919302106
A Rapid Allele-Specific Assay for HLA-A*32:01 to Identify Patients at Risk for Vancomycin-Induced Drug Reaction with Eosinophilia and Systemic Symptoms: https://pubmed.ncbi.nlm.nih.gov/31158526/
Severe delayed cutaneous and systemic reactions to drugs: a global perspective on the science and art of current practice: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5424615/
Applications of Immunopharmacogenomics: Predicting, Preventing, and Understanding Immune-Mediated Adverse Drug Reactions: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6409210/
Successful translation of pharmacogenetics into the clinic: the abacavir example: https://pubmed.ncbi.nlm.nih.gov/19351209/
HLA and pharmacogenetics of drug hypersensitivity: https://pubmed.ncbi.nlm.nih.gov/22920398/
Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy:  https://pubmed.ncbi.nlm.nih.gov/24565765/
Recent advances in the understanding of severe cutaneous adverse reactions: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5582023/
Penicillin Allergy:
https://www.nejm.org/doi/full/10.1056/NEJMra1807761



Show Notes

In this episode, we talk with world-renowned DRESS Syndrome expert, Dr. Elizabeth Phillips. She and her colleagues at Vanderbilt University Medical Center are working to better understand the genetic factors that increase a patient's risk for developing  life-threatening, immune-mediated drug reactions - with a focus on simple, inexpensive diagnostic tests can save countless lives.

Interview: Dr. Elizabeth J. Phillips (Professor of Medicine, Pharmacology, Pathology, Microbiology and Immunology and is Director of Personalized Immunology at the Oates Institute for Experimental Therapeutics at Vanderbilt University Medical Center. Lead Scientific Advisor for DRESS Syndrome Foundation) August, 2019 in Bethesda, MD

PUBLICATIONS/RESOURCES:

Vanderbilt Institute for Infection, Immunology and Inflammation: https://www.vumc.org/viiii/person/elizabeth-j-phillips-md
HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms: https://www.sciencedirect.com/science/article/pii/S0091674919302106
A Rapid Allele-Specific Assay for HLA-A*32:01 to Identify Patients at Risk for Vancomycin-Induced Drug Reaction with Eosinophilia and Systemic Symptoms: https://pubmed.ncbi.nlm.nih.gov/31158526/
Severe delayed cutaneous and systemic reactions to drugs: a global perspective on the science and art of current practice: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5424615/
Applications of Immunopharmacogenomics: Predicting, Preventing, and Understanding Immune-Mediated Adverse Drug Reactions: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6409210/
Successful translation of pharmacogenetics into the clinic: the abacavir example: https://pubmed.ncbi.nlm.nih.gov/19351209/
HLA and pharmacogenetics of drug hypersensitivity: https://pubmed.ncbi.nlm.nih.gov/22920398/
Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy:  https://pubmed.ncbi.nlm.nih.gov/24565765/
Recent advances in the understanding of severe cutaneous adverse reactions: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5582023/
Penicillin Allergy:
https://www.nejm.org/doi/full/10.1056/NEJMra1807761